On April 7th, the FDA’s Gastrointestinal Drug Advisory Committee (GIDAC) voted unanimously (17 to 0) in favor of the accelerated approval of Ocaliva (obeticholic acid) for the treatment of primary biliary cirrhosis (PBC). PBC is a rare chronic liver condition and if left untreated can progress to hepatic fibrosis, cirrhosis, liver failure and death.
On April 7th, the FDA’s Gastrointestinal Drug Advisory Committee (GIDAC) voted unanimously (17 to 0) in favor of the accelerated approval of Ocaliva (obeticholic acid) for the treatment of primary biliary cirrhosis (PBC). PBC is a rare chronic liver condition and if left untreated can progress to hepatic fibrosis, cirrhosis, liver failure and death. If approved, Ocaliva (Intercept Pharmaceuticals, Inc.) would be the first treatment for PBC in nearly 20 years.
The panel’s recommendation was based on data from a total of 432 PBC patients. However, the committee primarily relied on data from the Phase III POISE trial, which assessed the safety and efficacy of Ocaliva in 216 PBC patients.
Accelerated approval is granted by the FDA based on a surrogate endpoint that indicates a clinical benefit. The FDA Accelerated Approval Program allows for earlier approval of drugs that treat serious conditions, and address an unmet medical need. Intercept is currently moving forward with a Phase IV long-term outcomes trial for Ocaliva in patients living with PBC, as sponsors are required to confirm the anticipated benefit. Moreover, the FDA can retract approval if a confirmatory trial is not supportive of such a benefit.
The agency is not obligated to follow its panel’s recommendation, but normally does so.
ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact firstname.lastname@example.org
Do you have an upcoming Advisory Committee Meeting?
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us